晚期喉癌边缘DNA含量和增殖细胞核抗原表达

目的 探讨晚期喉癌边缘ＤＮＡ含量和增殖细胞核抗原（ＰＣＮＡ）表达与喉癌手术预后的关系。方法 通过ＰＣＮＡ表达和ＤＮＡ含量检测，对３４例晚期喉癌边缘进行观察。结果 肿瘤边缘１．０、０．５、０ｃｍ处粘膜，ＰＣＮＡ指数分别为８．６２％，１７．７６％和５０．３２％。ＤＮＡ指数分别为０．９８、１．０８２和１．４３６。统计学分析１．０、０．５ｃｍ处粘膜０ｃｍ处粘膜差异有显著性（Ｐ〈０．０１）。结论 中、重度非     

喉癌组织中增殖细胞核抗原的表达及意义

喉癌组织中增殖细胞核抗原的表达及意义季文樾，关超，费声重增殖细胞核抗原（ＰｒｏｌｉｆｅｒａｔｉｎｇＣｅｌｌＮｕ－ｃｌｅａｒＡｎｔｉｇｅｎ，ＰＣＮＡ）是近年新兴的原位检测增殖细胞活检的免疫化学探针。我们用抗ＰＣＮＡ的单抗和免疫组化技术，对喉鳞癌作了研究...     

增殖细胞核抗原（PCNA）,DNA含量及细胞核形态参数测定在鼻咽…

应用增殖细胞核抗原单克隆抗体ＰＣ１０免疫组化法，ＤＮＡ含量及细胞核形态图像分析法，对５８例鼻咽癌进行检测。结果显示，三种方法的检测结果具有较好的一致性，其中肿瘤细胞的ＤＮＡ指数和ＤＮＡ倍体分布最具有价值。结果表明，检测肿瘤细胞增殖活性对于判断鼻咽癌恶性变及估计患者的预后具有重要意义。     

喉癌磁共振成像信号强度0与增殖细胞核抗原表达相关性

目的探讨喉癌组织磁共振成像(magneticresonanceimaging,MRI)相对信号强度与其增殖细胞核抗原(proliferatingcellnuclearantigen,PCNA)表达的关系。方法20例喉癌患者,术前行磁共振SE序列平扫以及增强SE序列T1WⅠ扫描、动态增强T1WⅠ扫描。术后应用ABC免疫组化法对喉癌标本的PCNA含量进行半定量测量。结果MRI相对信号强度增加值:增殖细胞核抗原标记指数>50%组为0.28±0.20;增殖细胞核抗原标记指数大于5%,小于或等于50%组为0.66±0.22,两组比较P<0.05两组信号强度达峰值的时间分别为5.58±2.54和8.38±3.66秒,二者比较P=0.058。结论MRI信号强度在一定程度上可以反映肿瘤细胞的恶性度,对判断肿瘤生物学特征及推测预后有一定参考意义。     

P53蛋白及增殖细胞核抗原（PCNA）在喉癌细胞中的表达及意义

采用ＡＢＣ免疫组化法对７８例喉癌行回顾性及前瞻性研究，测定喉癌细胞Ｐ５３蛋白及增殖细胞核抗原的表达，结果临床病理及随访资料对Ｐ５３蛋白过度表达在喉癌发生发展中的作用及意义进行探讨。     

喉鳞癌中增殖细胞核抗原和p53蛋白表达的临床意义及其…

本文以ＬＳＡＢ免疫组化方法，用单克隆抗体ＰＣ１０和ＤＯ－１对３０例喉鳞癌及１０例对照组（声带息肉）的增殖细胞核抗原（ＰＣＮＡ）与ｐ５３蛋白表达进行研究，探讨其生物学意义。结果表明；１）喉鳞癌组织ＰＣＮＡ阳性表达率为１００％（ＰＣＮＡ－Ｌｌｓ１６％～９２％），强阳性率为３６．７％（１１／３０），对照组６例阴性，４例弱阳性表达（ＰＣＮＡ－ＬＩｓ〈１０％），试验组阳性表达率及表达程度明显高于对照组（Ｐ〉     

增殖细胞核抗原表达及在头颈肿瘤研究中的应用

增殖细胞核抗原（ｐｒｏｌｉｆｅｒａｔｉｎｇｃｅｌｌｎｕｃｌｅａｒａｎｔｉｇｅｎ，ＰＣＮＡ）近年来广泛应用于评价肿瘤细胞增殖状态，本介绍了ＰＣＮＡ的生物特性，评价细胞增殖状态的价值及在头颈肿瘤研究中的应用。     

增殖细胞核抗原在鼻咽癌中表达的定量研究

为了增加鼻咽癌的诊断和预后判定指标，应用抗增殖细胞核抗原（ＰＣＮＡ）单克隆抗体，采用免疫组化染色ＬＡＳ－ＳＰ法及图象分析技术，对８２例鼻咽鳞状细胞癌和２５例鼻咽粘膜炎症组织标本进行了定量研究，并对鼻咽癌患者５年生存率与ＰＣＮＡ表达情况进行了相关性分析。结果：①根据ＰＣＮＡ阳性细胞计算的鼻咽癌细胞增殖指数与鼻咽癌的病理分级呈明显的正相关，与患者５年生存率呈明显负相关。②图像处理检测的ＰＣＮＡ表达量与     

增殖细胞核抗原在鼻咽癌中表达的定量研究

为了增加鼻咽癌的诊断和预后判定指标，应用抗增殖细胞核抗原（ｐｒｏｌｉｆｅｒａｔｉｎｇｃｅｌｎｅｃｌｅａｒａｎｔｉｇｅｎ，ＰＣＮＡ）单克隆抗体，采用免疫组化染色ＬＡＳ－ＳＰ法及图象分析技术，对８２例鼻咽鳞状细胞癌和２５例鼻咽粘膜炎症组织标本进行了定量研究，并对鼻咽癌患者５年生存率与ＰＣＮＡ表达情况进行了相关性分析。结果：①根据ＰＣＮＡ阳性细胞计算的鼻咽癌细胞增殖指数与鼻咽癌的病理分级呈明显的正相关，与患者５年生存率呈明显负相关。②图像处理检测的ＰＣＮＡ表达量与鼻咽癌的病理分级也呈明显的正相关，与５年生存率呈负相关，但泡状核细胞癌虽属低分化鳞癌却不符合上述规律。结论：ＰＣＮＡ能很好地反映鼻咽癌的增殖活性，在临床病理上具有应用前景，可作为对鼻咽癌预后判定及指导临床治疗的指标     

Clinical application of proliferating cell nuclear antigen, oncoprotein p53 and tumor front grading analysis in patients operated on for laryngeal cancer

The authors assessed proliferating cell nuclear antigen (PCNA), p-53 oncoprotein and morphologic tumor front grading (TFG) in patients with advanced squamous cell carcinoma (SCC), of the larynx and a poor prognosis and tried to find a correlation with tumor stage, the Broders grading system, local and neck lymph node metastases, as well as nodal and local recurrences. In addition, utility of the parameters investigated was evaluated in developing a prognostic factor model, using uni- and multivariate Cox regression analysis. Included in this study were 54 patients (mean age 57 years ± 8.6). PCNA-positive staining was found in all but one patient with advanced disease, while p-53 stained positively in only 24 subjects (44.4%). The PCNA index ranged from 4.6 to 59.0% (mean, 23.4 ± 11.0) and the p-53 index varied from 4.0 to 42.0% (mean, 17.2 ± 8.6). The TFG score ranged from 9 to 23 points (mean, 15.1 ± 3.2). PCNA, p-53 and TFG were found to be the markers that provided significant additional information about the biological behavior of tumor cells. The high variability of the results (PCNA, p-53) and high percentage of negatively stained cells (p-53) reduced their application in clinical use. PCNA correlated with tumor grade, G (r = 0.38; P < 0.01), but negatively with nodal (N) disease(r = –0.37; P < 0.01). The mean values of PCNA and p-53 index were higher in the subgroup with local recurrences. Our present attempt to develop a useful prognostic factor model failed. Received: 26 September 1998 / Accepted: 1 March 1999     

Immunohistochemical detection of proliferating cell nuclear antigen in middle ear cholesteatoma

Cholesteatoma epithelium is characterized by a keratinocyte dysregulation accompanied by destruction of the ossicles and temporal bone. Immunohistochemical methods using antibodies to cell-cycle-related antigens can be used as a means for assessing various aspects of proliferation in cholesteatoma tissue. They also have the important advantage of preserving the spatial orientation of proliferating cells in histological sections. Proliferating cell nuclear antigen (PCNA) is a 36 kDa DNA-delta-polymerase-associated protein that is directly involved in the mechanisms of DNA synthesis. In the present study the expression of PCNA was investigated in formalin-fixed, paraffin-embedded biopsy specimens of cholesteatomas and normal skin. Normal skin revealed nuclear staining in a small number of keratinocytes (PCNA grade, 1.5) located in the basal cell layer. In contrast, an increased number of PCNA-labeled basal and suprabasal epidermal cells (PCNA grade, 9.3) were found in cholesteatoma samples. Our findings indicate that PCNA represents a reliable marker for epithelial proliferation, showing that cholesteatoma epithelium proliferates at a higher rate than normal epidermis. These findings also support the concept of keratinocyte dysregulation in middle ear cholesteatoma.     

下咽癌细胞增殖细胞核抗原及其基因的表达研究

目的 :通过对下咽癌细胞增殖细胞核抗原 (PCNA)及其基因的检测 ,以探讨其对下咽癌生物学特性、临床行为及预后的影响。方法 :用免疫组织化学染色SABC法检测 4 8例下咽癌手术标本和同期 1 5例癌旁正常组织标本PCNA的表达 ,计算其增殖指数 ;同时用寡核苷酸探针原位杂交技术检测PCNA的mRNA ,以检验免疫组化与原位杂交结果的一致性。结果 :下咽癌组PCNA增殖指数为 (71 .4 8± 1 1 .1 4 ) % ,对照组为 (2 1 .1 3±1 2 .0 7) % ,其差异有显著性意义 (P <0 .0 5 ) ;PCNA增殖指数与癌的临床分期、组织分化程度及预后相关 ,而与是否有颈淋巴结转移和肿瘤发生部位无明显关系 ,且免疫组化和原位杂交两种检测结果相一致 (符合率为 85 .7% )。结论 :检测下咽癌PCNA的表达可能对判断肿瘤恶性程度及预后有一定的参考价值     

喉癌EGFR和PCNA表达及DNA含量的研究

研究喉鳞癌中表皮生长因子受体、增殖细胞核抗原的表达和ＤＮＡ含量,分析各指标间的相关性及与喉癌临床生物学行为和预后的关系。方法：用免疫组化ＳＰ法和图像分析仪检测正常喉粘膜、喉鳞癌的ＥＧＦＲ、ＰＣＮＡ和ＤＮＡ指数,结合临床资料进行分析。结果：喉鳞癌的ＥＧＦＲ的阳性表达率为５４．８％,与正常喉组织的差异有统计学意义,但ＥＧＦＲ的阳性表达与喉癌的病理分级和５年生丰率无显著相关,而ＰＣＮＡ阳性表达和ＤＩ则随     

Assessment of proliferating cell nuclear antigen immunostaining in parotid tumors

We evaluated the prognostic value of immunostaining proliferating cell nuclear antigen (PCNA) by using a monoclonal antibody (PC10) in patients with parotid tumors. Twenty-seven cases were studied. Immunohistochemical studies were carried out on paraffin-embedded tissues from the patients, and the PCNA index was calculated as the percentage of positively staining tumor cells. The PCNA index ranged from 0.1 to 65.3%. We divided the 27 lesions into three groups histologically: group A with benign pleomorphic tumors (11 cases), group B with low-grade malignant tumors (5 cases), and group C with high-grade malignant tumors (11 cases). The mean PCNA index was 0.7% in group A, 2.0% in group B, and 23.1% in group C. The clinical data revealed a significantly higher local tumor recurrence and mortality rate in group C than in groups A and B. We conclude that PCNA may be used as an important indicator for determining clinical prognosis in parotid tumors. Received: 26 July 1997 / Accepted: 28 October 1997     

增殖细胞核抗原和p53基因在鼻咽癌中的表达及相关性研究

目的:通过免疫组织化学方法检测鼻咽癌(NPC)患者增殖细胞核抗原(PCNA)、p53基因表达,分析其与主要临床指标间的关系。方法:免疫组织化学检测鼻咽活检组织中PCNA、p53蛋白表达,并比较与分析两者和NPC临床分期及颈淋巴结转移的关系。结果:鼻咽部慢性炎性组织中p53阳性率为9.5%,明显低于NPC组织中的阳性率(76.3%)(P<0.01)。NPC伴颈淋巴结转移组p53阳性率(90.9%)明显高于无颈淋巴结转移组(57.7%)(P<0.01),临床Ⅱ、Ⅲ和Ⅳ期p53阳性率(分别为93.3%、80.0%和100.0%)均明显高于临床Ⅰ期(40.0%)(均P<0.01),且表达强度有增加的趋势。随着临床分期的增高,PCNA增殖指数(PI)分级有增高的趋势,NPC伴颈淋巴结转移组中PCNAPI之Ⅰ级所占比例较无颈淋巴结转移组下降,而Ⅱ、Ⅲ、Ⅳ级所占比例增加,但无统计学意义,NPC组织中PCNA表达与p53表达显著相关(P<0.01)。结论:p53蛋白可作为NPC较好的肿瘤标记物,p53阳性的NPC患者较易发生颈淋巴结转移,随着NPC病程的发展,p53表达率及表达强度均增加,PCNAPI可反映NPC的增殖状况,可能与预后相关。     

成人型喉乳头状瘤中PCNA的表达和AgNORs的定量研究

探讨细胞增殖活性与成人型喉乳头状瘤生物学行为的关系。采用抗增殖细胞核抗原（ＰＣＮＡ）单克隆抗体ＰＣ１０，ＡＢＣ免疫组化法和银染技术，评价其细胞增殖活性。结果：经ＰＣＮＡ阳性反应计算出的ＰＣＮＡ增殖指数与核仁形成区嗜银蛋白（ＡｇＮＯＲｓ）计数间存在显著的相关性。经统计学分析有显著差异（Ｐ〈０．０５）。提示：ＰＣＮＡ表达和ＡｇＮＯＲｓ计数可作为喉部良、恶性病变的鉴别，检测癌前病变及观察肿瘤生物学行为较     

p21WAF1/CIP1和抑制增殖细胞核抗原的表达与下咽癌及喉癌的临床关系

目的：探讨p21^WAF1/CIP1和抑制增殖细胞核抗原(PCNA)的表达与下咽癌、喉癌的分级、转移及预后的关系,了解p21^WAF1/CIP1在下咽癌、喉癌发生、发展中的作用以及与PCNA的相关性。方法：对45例下咽癌、25例声门上型喉癌、23例声门型喉癌标本,用Envision HIS的方法检测p21^WAF1/CIP1、PCNA的表达情况,并分析p21^WAF1/CIP1表达与下咽癌、喉癌临床病理特征、转移、复发和预后的关系。结果：p21^WAF1/CIP1阳性表达率为51.6％(48／93),PCNA的阳性表达率为97.8％(91／93);p21^WAF1/CIP1表达与下咽癌、喉癌患者的年龄、性别、肿瘤分化、远处转移及复发无显著性相关,与肿瘤的原发部位的T分期有显著性相关;p2^WAF1/CIP1的表达还与肿瘤的预后有显著性相关;而PCNA与肿瘤的临床分期及淋巴转移有显著性相关,p21^WAF1/CIP1与PCNA的表达具有相关性。结论：p21^WAF1/CIP1、PCNA是预测肿瘤浸润范围及转移的良好指标,p21^WAF1/CIP1对预后的判定具有一定的指导意义。